3-(3-羟基苯基)-苯甲酸 | 171047-01-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(3-羟基苯基)-苯甲酸
• 中文别名: 3'-羟基联苯-3-羧酸
• 英文名称: 3'-hydroxybiphenyl-3-carboxylic acid
• 英文别名: 3'-Hydroxy-[1,1'-biphenyl]-3-carboxylic acid；3-(3-hydroxyphenyl)benzoic acid
• CAS: 171047-01-1
• 化学式: C₁₃H₁₀O₃
• 分子量: 214.221
• InChiKey: CTFCUBMVYRSJLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温下应保存于干燥密封的容器中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3’-Hydroxybiphenyl-3-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3’-Hydroxybiphenyl-3-carboxylic acid
CAS number: 171047-01-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H10O3
Molecular weight: 214.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(3-羟基苯基)-苯甲酸 在 氯化亚砜 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 氯仿 为溶剂， 反应 17.0h， 生成 methyl 3-[3-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]phenyl]benzoate
  参考文献：
  名称：

  CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

  摘要：

  公式（I）的构象受限、空间定义的大环环系统由三个不同的分子部分组成：模板A、构象调节剂B和桥C。由这种环系统I描述的大环可通过并行合成或溶液中或固相上的组合化学轻松制造。它们被设计用于与各种特定生物靶标类相互作用，例如在G蛋白偶联受体（GPCR）上的激动或拮抗活性，酶的抑制活性或抗菌活性。特别是，这些大环显示对亚型1的内皮素转化酶（ECE-1）和/或半胱氨酸蛋白酶卡特普辛S（CatS）的抑制活性，和/或作为催产素（OT）受体、促甲状腺释放激素（TRH）受体和/或白三烯B4（LTB4）受体的拮抗剂，和/或作为瘤胃素3（BB3）受体的激动剂，和/或对至少一种细菌菌株显示抗菌活性。因此，它们显示出作为各种疾病药物的巨大潜力。

  公开号：

  US20150051183A1
• 作为产物：
  描述：

  3-氟联苯-3-羧酸 在 dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer 、 水 、 silver trifluoromethanesulfonate 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以45%的产率得到3-(3-羟基苯基)-苯甲酸
  参考文献：
  名称：

  芳基氟化物的催化SNAr羟基化和烷氧基化

  摘要：

  亲核芳香取代 (S N Ar) 是一种通过用亲核试剂取代离去基团将杂原子结合到芳香环中的强大策略，但这种方法仅限于缺电子芳烃。我们现在已经建立了一种通过催化 S N Ar 反应获取苯酚和苯基烷基醚的可靠方法。该方法适用于广泛的富电子和中性芳基氟化物，它们在经典的 S N Ar 条件下呈惰性。虽然 S N的机制假设涉及金属芳烃配合物的 Ar 反应涉及逐步途径（添加后消除），支持该假设的实验数据仍在探索中。机械研究和 DFT 计算表明了一个逐步或逐步的能量分布。值得注意的是，我们分离了铑 η 5 -环己二烯基复合中间体，其具有带有亲核试剂和离去基团的 sp 3 -杂化碳。

  DOI：

  10.1002/anie.202106440

文献信息

• A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design
  作者：Sundus Akhter、Bjarte Aarmo Lund、Aya Ismael、Manuel Langer、Johan Isaksson、Tony Christopeit、Hanna-Kirsti S. Leiros、Annette Bayer

  DOI：10.1016/j.ejmech.2017.12.085

  日期：2018.2

  β-lactamase inhibitors and today several β-lactamase inhibitors e.g. avibactam, are approved in the clinic. Our focus is the oxacillinase-48 (OXA-48), an enzyme reported to spread rapidly across the world and commonly identified in Escherichia coli and Klebsiella pneumoniae. To guide inhibitor design, we used diversely substituted 3-aryl and 3-heteroaryl benzoic acids to probe the active site of OXA-48

  当在医学界中治疗细菌感染时，β-内酰胺抗生素至关重要。然而，目前它们的效用受到β-内酰胺抗性的出现和扩散的威胁。对β-内酰胺抗生素最普遍的耐药机制是β-内酰胺酶的表达。克服由β-内酰胺酶引起的抗性的一种方法是开发β-内酰胺酶抑制剂，如今临床上已经批准了几种β-内酰胺酶抑制剂，例如阿维巴坦。我们的研究重点是oxacillinase-48（OXA-48），据报道该酶在世界范围内迅速传播，通常在大肠杆菌和肺炎克雷伯菌中得到鉴定。为了指导抑制剂的设计，我们使用了不同取代的3-芳基和3-杂芳基苯甲酸来探测OXA-48的活性位点，以进行有用的酶-抑制剂相互作用。在本研究中，合成了包含49个3-取代的苯甲酸衍生物的聚焦片段文库，并对其进行了生化表征。基于从33片段的酶复合物晶体学数据，片段可以被归类为R 1或R 2个可以通过总体结合构象相对于粘合剂到R的结合1和R 2亚胺培南的侧基。此外，发现了对未来抑
• [EN] CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS MACROCYCLIQUES ENTIÈREMENT SYNTHÉTIQUES ET À CONFORMATION CONTRAINTE
  申请人：POLYPHOR AG

  公开号：WO2013139697A1

  公开（公告）日：2013-09-26

  The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1 ) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.

  公式（I）的构象受限、空间定义明确的大环环形系统由三个不同的分子部分构成：模板A、构象调制剂B和桥梁C。由该环系统I描述的大环可通过溶液中的并行合成或组合化学，或者在固相上制造。它们被设计用来与各种特定生物靶标类相互作用，例如在G蛋白偶联受体（GPCR）上的激动或拮抗活性，对酶的抑制活性或抗菌活性。特别是，这些大环显示对第1亚型内皮素转化酶（ECE-1）和/或半胱氨酸蛋白酶S（CatS）的抑制活性，和/或作为催产素（OT）受体、促甲状腺释放激素（TRH）受体和/或白三烯B4（LTB4）受体的拮抗剂，和/或作为瘤胃肽3（BB3）受体的激动剂，和/或对至少一种细菌菌株显示抗菌活性。因此，它们显示出作为各种疾病药物的巨大潜力。
• 4,5-diaryloxazole derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06025375A1

  公开（公告）日：2000-02-15

  Heterocyclic compounds of the formula: ##STR1## whereinR.sup.1 is carboxy or protected carboxy, R.sup.2 is aryl which may have suitable substituent(s), R.sup.3 is aryl which may have suitable substituent(s), A.sup.1 is lower alkylene, A.sup.2 is bond or lower alkylene and -Q- is ##STR2## etc., and pharmaceutically acceptable salts thereof which are useful as a medicament.

  式为：##STR1##其中R.sup.1是羧基或保护羧基，R.sup.2是芳基，可能有适当的取代基，R.sup.3是芳基，可能有适当的取代基，A.sup.1是较低的烷基，A.sup.2是键或较低的烷基，-Q-是##STR2##等，以及其药学上可接受的盐，可用作药物。
• Improving the Adjuvanticity of Small Molecule Immune Potentiators Using Covalently Linked NF-κB Modulators
  作者：Flora W. Kimani、Saikat Manna、Brittany Moser、Jingjing Shen、Naorem Nihesh、Aaron P. Esser-Kahn

  DOI：10.1021/acsmedchemlett.1c00267

  日期：2021.9.9

  we report the design and synthesis of novel imidazoquinolinone-NF-κB immunomodulator dimers. Employing in vitro assays, we screened a select library of synthesized dimers and selected viable candidates for further in vivo experiments. With ovalbumin as a model antigen, we vaccinated mice and demonstrated that these dimers reduce the systemic toxicity associated with SMIPs to baseline levels while simultaneously

  小分子免疫增强剂 (SMIP)，例如激活 Toll 样受体 (TLR) 7/8 的咪唑喹啉酮衍生物，具有作为疫苗佐剂和抗肿瘤剂的巨大潜力。然而，这些分子具有高生物利用度，由于佐剂毒性导致不可接受的全身炎症水平，从而极大地限制了它们的使用。为了应对这一挑战，我们在这里报告了新型咪唑喹啉酮-NF-κB 免疫调节剂二聚体的设计和合成。采用体外检测，我们筛选了合成二聚体的精选文库，并选择了可行的候选物用于进一步的体内试验实验。使用卵清蛋白作为模型抗原，我们给小鼠接种疫苗并证明这些二聚体将与 SMIP 相关的全身毒性降低到基线水平，同时保持疫苗制剂的佐剂性。此外，我们表明选择的二聚体提高了 CT26 小鼠结肠癌肿瘤模型的疗效，同时引起最小的佐剂毒性。
• [EN] NOVEL SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1<br/>[FR] NOUVEAUX INHIBITEURS SÉLECTIFS DE LA 11-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
  申请人：DSM IP ASSETS BV

  公开号：WO2017012890A1

  公开（公告）日：2017-01-26

  The present invention relates to novel selective 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and the use thereof to prevent age-induced skin structure and function defects.

  本发明涉及新型选择性11-β-羟基类固醇脱氢酶1（11β-HSD1）抑制剂及其用途，用于预防年龄诱导的皮肤结构和功能缺陷。